AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- A Canadian electric vehicle (EV) manufacturer’s stock has added a massive 1068 per cent growth in 2020. The stock has swelled by 566 per cent in the last six months.
- The EV producer also made it to TMX’s top price performer, rising star, and top consumer goods stock lists.
- An Ontario-based biotech company’s stock has flourished with an amazing 1271 per cent gains this year. The company is focused on developing therapies for cancer patients.
When investors decide to put their money in equity markets, growth stocks are mostly on their radar. In the pandemic-roiled markets of 2020, two stocks have been able to fly, yielding 1000+ per cent returns this year. These skyrocketing stocks have managed to surpass the returns of benchmark Canadian indices and markets, propelled by a core emphasis on revenue growth and profit margin surge.
We’re referring to GreenPower Motor Company and Trillium Therapeutics. Let us look at their current market fundamentals and financials:
GreenPower Motor Company Inc. (TSXV:GPV)
Current Stock Price: C$ 23.30
This electric vehicle (EV) manufacturer has yielded over 1068 per cent in 2020 (YTD). With a Tesla-led rally in North America, the investors have been bullish on EV stocks this year. Riding on the wave, this stock has surged almost 566 per cent in the last six months. The EV firm stocks have climbed by approximately 77 per cent in the last one month.
The EV company is placed among TMX’s Top Price Performer list – stocks that have the largest returns across the TSX and TSXV in the last 30 days. Greenpower also ranks on TMX’s top consumer good companies that have outperformed their peers in the last 30 days, as per TMX data.
GreenPower’s current market capitalization stands at C$ 445 million.
Its price-to-book (P/B) ratio is 10.043, and its price-to-cashflow (P/CF) ratio is 9.30. Its current debt-to-equity (D/E) ratio is 0.72, according to the TMX portal.
In the second quarter of fiscal 2020, the EV maker registered revenue of US$ 2.8 million making a gross profit of 31.2 per cent of revenue. The company reported cash expenditures of US$ 1.7 million before sales in line with Q2 FY20.
Trillium Therapeutics Inc. (TSX:TRIL)
Current Stock Price: C$ 15.49
This biotech company is developing solutions for the treatment of cancer. Trillium stocks have gained an astonishing 1271 per cent this year. In the last six months, the stock has increased by over 49 per cent.
The healthcare firm operates only in the research and development (R&D) segment. Its current lead study program is TTI-621, and the company also has a proprietary medicinal chemistry platform utilizing fluorine chemistry, which allows the formation of new chemical entities.
In the third quarter of 2020, the biotech firm reported clinical data for both TTI-622 and TTI-621, also received an equity investment of US$ 25 million from Pfizer, and raised US$ 150 million in a follow-on offering.
Trillium held cash and cash equivalents and marketable securities of US$ 292.4 million as of September 30, 2020, versus US$ 22.7 million in Q3 2019.
